scholarly journals Circulating serum vitamin D levels and total body bone mineral density: A Mendelian randomization study

2019 ◽  
Vol 23 (3) ◽  
pp. 2268-2271 ◽  
Author(s):  
Jing-yi Sun ◽  
Ming Zhao ◽  
Yajun Hou ◽  
Cheng Zhang ◽  
Jinrok Oh ◽  
...  
2019 ◽  
Vol 49 (4) ◽  
pp. 292-298
Author(s):  
Indar K Sharawat ◽  
Lesa Dawman ◽  
Merabhai V Kumkhaniya ◽  
Kusum Devpura ◽  
Amarjeet Mehta

Glucocorticoids are first-line therapy for children with idiopathic nephrotic syndrome (INS). These children are at risk of deranged bone metabolism and low bone mineral density (BMD). We studied 60 children with INS and divided them into two groups. Group 1 included 21 children (initial and infrequent relapsing) and group 2 included 39 children (frequent relapsing, steroid dependent and steroid resistant). Dual-energy X-ray absorptiometry of the lumbar spine was performed to assess BMD. Mean BMD Z-score was compared in both groups; this correlated significantly on univariate analysis with cumulative steroid dose, serum vitamin D levels and calcium supplementation. However, on multivariate analysis, serum vitamin D level was the only factor significantly predictive of low z-score.


2016 ◽  
Vol 3 (64) ◽  
pp. 3515-3519
Author(s):  
Selvapandian Kirubaharan S ◽  
Arshiya Begum ◽  
Priya Anbarasan ◽  
Latha Jeyasubramanian ◽  
Santhi Natesan ◽  
...  

Author(s):  
Anubha Garg ◽  
Surekha Dabla ◽  
Sandeep Nagenhalli ◽  
Sanjay Fotedar

Background: Objective of the study was to determine the Levetiracetam monotherapy effect on serum calcium and serum vitamin D levels in tertiary care hospital in Haryana, India.Methods: A total of 110 patients with epilepsy, were enrolled to the study for one year between April 2013 to August 2014. All male patients aged 15-60 years and premenopausal females with epilepsy were included in the study. The study was a interventional prospective study design. The antiepileptic drug levetiracetam was administered starting from a dose of 20 mg/kg and dose was titrated according to the clinical response. During the follow up period, the subjects were asked about the seizure frequency and other side effects. The patients were be subjected to questionnaires based proforma. Baseline investigations, Hemogram, renal and liver function tests, calcium, phosphate, vitamin D and bone mineral density and T scores were noted. All investigations were repeated after one year of levetiracetam monotherapy.Results: The mean age of onset of seizures in the study group was 23.22±6.62 years. 58% (n=29) were seizure free after 1 year of levetiracetam monotherapy, 28% patients had adequate control and 14% patients had poor control of their seizure episodes. There was an insignificant change in Hemoglobin, total leukocyte count, platelet count, renal parameters and Liver enzymes from baseline over a year of levetiracetam therapy. Serum calcium levels increased insignificantly from baseline levels of 9.68±0.59 mg/dl to 9.72±0.56mg/dl. Vitamin D levels increased from baseline of 39.35±14.91ng/ml to 39.84±14.07 ng/ml. Bone mineral density increased insignificantly from baseline of 0.92±0.13 g/cm2 to 0.93±0.13 g/cm2.Conclusions: Present study has shown an overall beneficial effect on serum calcium, Vitamin D level, bone mineral density and T scores on DEXA scan.


2019 ◽  
Vol 26 (3) ◽  
pp. 145 ◽  
Author(s):  
Hee-Sook Lim ◽  
Dong Won Byun ◽  
Kyo Il Suh ◽  
Hyeong Kyu Park ◽  
Hye Jeong Kim ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Sundus Tariq ◽  
Saba Tariq ◽  
Saba Khaliq ◽  
Mukhtiar Baig ◽  
Manal Abdulaziz Murad ◽  
...  

BackgroundResistin is a relatively novel adipokine that has a role in bone remodeling and may regulate bone mineral density (BMD). Vitamin D and adipokines have a dynamic role in the body’s various metabolic processes, including bone metabolism, and may alter bone metabolism in relation to each other. This study aimed to investigate the association between vitamin D and serum resistin levels in postmenopausal non-osteoporotic and osteoporotic females.MethodsThis correlational analytical study was conducted on 161 postmenopausal females, divided into two groups, non-osteoporotic and osteoporotic, between 50–70 years. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry (DXA) scan. Serum resistin and vitamin D levels were analyzed by enzyme-linked immunosorbent assay (ELISA) method. Serum calcium, phosphate, and alkaline phosphatase with spectrophotometry. A correlation was checked using spearman’s rho correlation coefficient, and multivariate stepwise regression analysis was used to predict serum resistin levels.ResultsPostmenopausal females (n=161) having sufficient, insufficient and deficient levels of vitamin D were 87 (54.0%), 64 (39.8%), and 10 (6.2%), respectively. Lumbar spine BMD (p < 0.001), total hip BMD (p < 0.001), and serum resistin levels (p < 0.001) were significantly different between the two groups. There was a significant negative correlation between serum resistin and vitamin D in postmenopausal females (rho = -0.182, p = 0.021) and osteoporotic group (rho = -0.253, p = 0.019) but non-significant in non-osteoporotic group (rho = -0.077, p = 0.509). Serum vitamin D was found to be independent predictor of serum resistin levels, accounting for only 3% variance.ConclusionSerum vitamin D levels were low while serum resistin levels were high in postmenopausal osteoporotic females and vitamin D is a negative predictor of serum resistin levels.


2004 ◽  
Vol 92 (1) ◽  
pp. 159-168 ◽  
Author(s):  
Xueqin DU ◽  
Kun Zhu ◽  
Angelika Trube ◽  
Qian Zhang ◽  
Guansheng Ma ◽  
...  

AbstractA 2-year milk intervention trial was carried out with 757 girls, aged 10 years, from nine primary schools in Beijing (April 1999 – March 2001). Schools were randomised into three groups: group 1, 238 girls consumed a carton of 330 ml milk fortified with Ca on school days over the study period; group 2, 260 girls received the same quantity of milk additionally fortified with 5 or 8 μg cholecalciferol; group 3, 259 control girls. Anthropometric and bone mineralisation measurements, as well as dietary, health and physical-activity data, were collected at baseline and after 12 and 24 months of the trial. Over the 2-year period the consumption of this milk, with or without added cholecalciferol, led to significant increases in the changes in height (≥0·6%), sitting height (≥0·8%), body weight (≥2·9%), and (size-adjusted) total-body bone mineral content (≥1·2%) and bone mineral density (≥3·2%). Those subjects receiving additional cholecalciferol compared with those receiving the milk without added 25-hydoxycholecalciferol had significantly greater increases in the change in (size-adjusted) total-body bone mineral content (2·4v. 1·2%) and bone mineral density (5·5v. 3·2%). The milk fortified with cholecalciferol significantly improved vitamin D status at the end of the trial compared with the milk alone or control groups. It is concluded that an increase in milk consumption, e.g. by means of school milk programmes, would improve bone growth during adolescence, particularly when Ca intake and vitamin D status are low.


Sign in / Sign up

Export Citation Format

Share Document